Candriam S.C.A. Has $82.28 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Candriam S.C.A. increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 35.5% in the second quarter, HoldingsChannel reports. The firm owned 389,152 shares of the medical research company’s stock after purchasing an additional 102,031 shares during the period. Candriam S.C.A.’s holdings in IQVIA were worth $82,278,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Private Advisor Group LLC increased its holdings in shares of IQVIA by 8.1% during the 2nd quarter. Private Advisor Group LLC now owns 5,078 shares of the medical research company’s stock valued at $1,074,000 after acquiring an additional 379 shares during the last quarter. Impax Asset Management Group plc grew its holdings in IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after purchasing an additional 264,555 shares during the last quarter. Arizona State Retirement System raised its position in shares of IQVIA by 0.8% in the second quarter. Arizona State Retirement System now owns 52,766 shares of the medical research company’s stock valued at $11,157,000 after purchasing an additional 394 shares during the period. 9258 Wealth Management LLC lifted its stake in shares of IQVIA by 6.5% in the second quarter. 9258 Wealth Management LLC now owns 2,965 shares of the medical research company’s stock worth $627,000 after buying an additional 181 shares during the last quarter. Finally, First Business Financial Services Inc. boosted its holdings in shares of IQVIA by 9.7% during the 2nd quarter. First Business Financial Services Inc. now owns 9,213 shares of the medical research company’s stock worth $1,948,000 after buying an additional 818 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on IQV. Evercore ISI lifted their target price on shares of IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Barclays raised their target price on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group initiated coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Royal Bank of Canada started coverage on shares of IQVIA in a research note on Wednesday. They issued an “outperform” rating and a $275.00 price objective on the stock. Finally, Truist Financial upped their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $266.67.

IQVIA Stock Down 2.0 %

NYSE IQV opened at $243.10 on Friday. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock’s 50 day moving average is $234.92 and its two-hundred day moving average is $234.63. The company has a market capitalization of $44.29 billion, a price-to-earnings ratio of 33.21, a PEG ratio of 2.37 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.